Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.54 |
| ▸ | FNTB | P49356 | 16/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HRAS | P01112 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650724 | 0.87 | FNTA (0.55) | FNTAFNTBTHRBHRASKRAS | |
| SCHEMBL12920276 | 0.87 | FNTA (0.55) | FNTAFNTBTHRBHRASKRAS | |
| SCHEMBL10183070 | 0.87 | FNTA (0.55) | FNTAFNTBTHRBHRASKRAS | |
| SCHEMBL648851 | 0.85 | FNTA (0.71) | FNTAFNTBTHRBMTNR1AMTNR1B | |
| SCHEMBL653554 | 0.85 | FNTA (0.71) | FNTAFNTBTHRBMTNR1AMTNR1B | |
| SCHEMBL648852 | 0.85 | FNTA (0.71) | FNTAFNTBTHRBMTNR1AMTNR1B | |
| SCHEMBL12894283 | 0.83 | MTNR1A (0.41) | FNTAFNTBMTNR1AMTNR1B | |
| SCHEMBL3283969 | 0.81 | MTNR1A (0.47) | FNTAFNTBMTNR1AMTNR1BHDAC1 | |
| SCHEMBL3285637 | 0.81 | MTNR1A (0.47) | FNTAFNTBMTNR1AMTNR1BHDAC1 | |
| SCHEMBL3283976 | 0.81 | MTNR1A (0.47) | FNTAFNTBMTNR1AMTNR1BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119808-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7884113-B2 | Tetrahydroquinoline derivatives as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104315-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | FNTA 1368/4885FNTB 2071/4885THRB 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.